Figures and Tables

From the following article:

Methylation inhibitor therapy in the treatment of myelodysplastic syndrome

Lewis R Silverman and Ghulam J Mufti

Nature Clinical Practice Oncology (2005) 2, S12-S23
doi:10.1038/ncponc0347

BACK TO ARTICLE
Figure 1 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Figure 1

CALGB (Cancer and Leukemia Group B) 9221: Median time to transformation to acute myeloid leukemia or death in patients with myelodysplastic syndrome treated with azacitidine or given best supportive care

Full size and legend (18K)Download PowerPoint slide (226K)
Figure 2 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Figure 2

CALGB (Cancer and Leukemia Group B) 9221: Survival from landmark data according to crossover status (Kaplan–Meier method)

Full size and legend (19K)Download PowerPoint slide (227K)
Figure 3 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Figure 3

CALGB (Cancer and Leukemia Group B) 9221: Fatigue, dyspnea, and physical functioning, as recorded on the EORTC (European Organization for Research and Treatment of Cancer) questionnaire, of patients with myelodysplastic syndrome who crossed over from supportive care to treatment with azacitidine (5-Aza-C) (n = 30)

Full size and legend (15K)Download PowerPoint slide (222K)
Figure 4 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Figure 4

CALGB (Cancer and Leukemia Group B) 9221: Physiological distress and well-being, as measured by the Mental Health Inventory (MHI), of patients who crossed over from supportive care to treatment with azacytidine (5-Aza-C) (n = 30)

Full size and legend (11K)Download PowerPoint slide (219K)
Figure 5 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Figure 5

Mechanism of action of DNA methyltransferase inhibitors and their incorporation into DNA

Full size and legend (44K)Download PowerPoint slide (245K)
Table 1 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Table 1

International Prognostic Scoring Systema for survival and acute myeloid leukemia evolution in myelodysplastic syndrome

Full size and legend Download PowerPoint slide (286K)
Table 2 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Table 2

Survival related to score on the International Prognostic Scoring System

Full size and legend Download PowerPoint slide (252K)
Table 3 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Table 3

CALGB 9221: Responses to azacitidine in patients with myelodysplastic syndromes, according to FAB subtype 14

Full size and legend Download PowerPoint slide (266K)
Table 4 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Table 4

Variable definitionsa of response between trials of DNA methyltransferase inhibitors

Full size and legend Download PowerPoint slide (441K)
BACK TO ARTICLE